1/17
High-yield vocabulary flashcards reviewing 2026 clinical guidelines in obstetrics and gynecology, covering cervical cancer screening, maternal immunization, Rh prophylaxis, DMPA contraception, postmenopausal bleeding workup, and thalassemia screening.
HPV Vaccination Campaign (India)
A free nationwide campaign launched in Feb 2026 targeting 1.15 crore girls aged 14 years with a single dose of Gardasil-4 (0.5mL IM in the left upper arm).
WHO 90-70-90 Elimination Target
Global cervical cancer targets calling for 90% of girls fully vaccinated by age 15 years, 70% of women screened at 35 and 45 years of age, and 90% of identified women receiving treatment.
ACS 2026 Cervical Screening (21–29 years)
Cervical cytology every 3 years.
ACS 2026 Cervical Screening (30–65 years)
Primary clinician-collected hrHPV every 5 years (preferred). If unavailable, options include co-testing every 5 years, patient-collected hrHPV every 3 years, or cytology every 3 years.
ACS 2026 Cervical Screening (≥65 years)
Routine screening is not indicated after adequate prior screening.
Tdap Maternal Immunization (ACOG 2026)
Administered during every pregnancy, preferably at 27–36 weeks of gestation, regardless of previous Tdap vaccination status.
Maternal Influenza Vaccine (ACOG 2026)
Inactivated or recombinant vaccine that can be given in any trimester during the influenza season.
Maternal COVID-19 Vaccine (ACOG 2026)
Vaccine that can be given in any trimester and should be administered as soon as possible.
RSV Vaccine (Pfizer Abrysvo)
Maternal immunization administered at 32%-36 weeks during the seasonal window (give ASAP).
Anti-D Immunoglobulin (<20 weeks)
Rh-D Ig dose of 150μg given after a sensitizing event occurring before 20 weeks of gestation.
Anti-D Immunoglobulin (After 20 weeks)
Rh-D Ig dose of 300μg given after a sensitizing event at or after 20 weeks of gestation (give ASAP; if delayed >72h, up to 10 days).
DMPA-SC
Subcutaneous depot medroxyprogesterone acetate formulated as 104mg/0.65mL (Antara-SC/Sayana Press) that is self-administrable.
DMPA-IM
Intramuscular depot medroxyprogesterone acetate formulated as 150mg (Antara).
Postmenopausal Bleeding Initial Evaluation (ACOG 2026)
The standard evaluation recommended for most patients with postmenopausal bleeding, consisting of transvaginal sonography (TVS) combined with endometrial tissue sampling.
TVS Without Biopsy Protocol in PMB
Protocol used initially only when all conditions are met: single episode of PMB, endometrium fully visualized, endometrial thickness ≤4mm, no strong risk factors for endometrial cancer, and prompt gynecologic follow-up available.
Strong Risk Factors for Endometrial Cancer
High-risk clinical factors in PMB including exogenous estrogen, SERM (e.g., Tamoxifen), BMI >30, nulliparity, Lynch/Cowden/family history, Black race, and diabetes mellitus.
Project MUKTA
"Mission to Unite and Keep Thalassemia Away"—an Indian screening initiative to detect carriers of β-thalassemia, sickle cell disease, and other Hb variants in all previously untested women, tested ideally before 8 weeks at the first ANC visit.
High-Performance Liquid Chromatography (HPLC) in Project MUKTA
The definitive technique of choice for thalassemia carrier screening, required because red-cell indices and Mentzer index alone are not sufficient for definitive diagnosis.